Respiratory failure medical therapy
Respiratory failure Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Respiratory failure medical therapy On the Web |
American Roentgen Ray Society Images of Respiratory failure medical therapy |
Risk calculators and risk factors for Respiratory failure medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
There is no treatment for respiratory failure; however, medication may be used to allow for easier intubation and to ease anxiety in the patient. Recently, studies have demonstrated a strong recommendation against the use of sedatives or analgesics. The use of these agents has been implicated in decreasing the success rates of ventilation mechanisms.
Medical Therapy
Medical therapy includes:[1][2]
- Naloxone:
- Naloxone is used as an antidote to opioid overdose - induced respiratory depression.
- Flumazenil:
- Flumazenil is used as an antidote in benzodiazepine overdose - induced respiratory depression.
- Sedatives, activated charcoal and gastric emptying are all not recommended except in the rare case of hypercapnic respiratory failure with progressive respiratory acidosis with:
- Anxiety
- Rapid shallow breathing
- Respiratory arrest
- Moderate to severe expiratory airway resistance
- Dynamic hyperinflation
Respiratory failure
- 1 Opiate overdose
- 1.1 Naloxone
- 1.1.1 Adult
- Preferred regimen (1): Naloxone 0.05 mg IV initially, then titrated in increasing amounts every 5 minutes with a respriatory rate of 12 or greater
- 1.1.1 Adult
- 1.1 Naloxone
- 2 Benzodiazepine overdose
- 2.1 Flumazenil
- 2.1.1 Adult
- Preferred regimen (1): Flumazenil 0.2 mg IV over 30 seconds
- Note (1): Repeated doses of 0.2 mg up to 1 mg if desired effect not achieved
- Note (2): Maximum dose of 3mg is given within any hour
- 2.1.1 Adult
- 2.1 Flumazenil
References
- ↑ Stoica RT, Macri A (2012). "[Sedation of patients with respiratory failure in ICU]". Pneumologia (in Romanian). 61 (4): 240–4. PMID 23424950.
- ↑ Bourenne J, Hraiech S, Roch A, Gainnier M, Papazian L, Forel JM (July 2017). "Sedation and neuromuscular blocking agents in acute respiratory distress syndrome". Ann Transl Med. 5 (14): 291. doi:10.21037/atm.2017.07.19. PMC 5537113. PMID 28828366.